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The Effect of Commercial Tests for Aneuploidy Screening Using Cell-free Fetal DNA
on Rates of Invasive Testing in Clinical Practice
Adetola Louis-Jacques, Courtney Burans, Sara Robinson, Elizabeth Schofield, Joanne Quinones, John Smulian, Meredith Rochon
Division of Maternal Fetal Medicine, Lehigh Valley Health Network, Allentown, PA, United States

ABSTRACT:
Objective: TTo determine the effect of new
commercial tests for aneuploidy screening
using cell free fetal DNA (cffDNA) on rates of
invasive testing.
Study Design: Commercial aneuploidy
screening tests using cffDNA were first offered
at Lehigh Valley Health Network Maternal
Fetal Medicine in late December 2011. All
patients offered cffDNA testing were at high
risk for fetal aneuploidy defined as advanced
maternal age, abnormal aneuploidy screening,
abnormal ultrasound findings and/or personal/
family history. Data regarding cffDNA test
rates, invasive testing rates (amniocentesis
and CVS) and indication for testing were
collected. Invasive testing indications were
further categorized into testing for aneuploidy
or for other indications. Chi square was used
to compare rates of invasive testing before and
after introduction of cffDNA testing.
Results: 365 patients underwent cffDNA
testing from 12/1/2011 to 12/30/2012. The
rates of invasive testing overall and invasive
testing for aneuploidy both decreased
significantly after introduction of cffDNA
testing as compared to before (P<0.001). The
difference in the number of invasive tests over
time was due to a decrease in procedures for
aneuploidy testing (Figure 1). The number of
cffDNA tests increased significantly from the
first half of 2012 to the second half of 2012
(P<0.001).
Conclusion: The new commercial tests
available for aneuploidy screening using cffDNA
were rapidly incorporated into clinical practice
and are associated with decreased use of
invasive tests.

INTRODUCTION:
In the past two decades, numerous strategies for the detection of fetal
aneuploidy have been developed, although definitifve diagnosis is possible only
through the use of invasive procedures. In the fall of 2011, non-invasive tests
for the diagnosis of common aneuploidies first became commercially available
for the diagnosis of common trisomies and sex chromosome abnormalities.
These tests work by identifying cffDNA in maternal blood with a high degrees
of sensitivity and specificity, and have the advantage of providing the patient
with highly accurate information without the discomfort or risk of an invasive
procedure. The purpose of this study is to characterize the use of cffDNA testing
at our institution and to see how the introduction of these tests has affected the
rate of invasive procedures performed over time.

METHODS:
•	Retrospective cohort study of all women undergoing cffDNA testing and/
or invasive testing for aneuploidy through Lehigh Valley Health Network
Maternal Fetal Medicine practice from 12/1/2011 – 12/30/2012.
– Consistent with ACOG guidelines, invasive testing for aneuploidy (amniocentesis
and CVS) is available to all women.
– CffDNA testing became available in late December 2011 in our practice and
was offered only to women at high risk for aneuploidy based on maternal
age, abnormal screening results, abnormal ultrasound findings, and/or family/
personal history of aneuploidy.
– All women underwent genetic counseling prior to invasive or cffDNA testing.
– Women with positive cffDNA results were strongly encouraged to undergo
invasive testing to confirm results.

•	Women undergoing invasive procedures and cffDNA testing during the
study period were identified by review of a MFM clinical and ultrasound
databases. Only women undergoing invasive testing for aneuploidy
detection were included in the analysis.
•	Medical records were reviewed for baseline characteristics, indications
for testing, test results and pregnancy outcomes. Neonatal records were
reviewed when available.
•	Descriptive statistics were generated for baseline characteristics and test
indications. Chi square was used to compare the rate of change in invasive
procedures and utilization of cffDNA over time.

RESULTS:
•	365 patients underwent cffDNA testing from 12/1/2011 to 12/30/2012.
•	The number of cffDNA tests increased significantly from the first half of 2012 to the second half of 2012 (143 vs. 222, P<0.001).
•	Rates of invasive testing for aneuploidy decreased significantly from 2011 (before cffDNA) to 2012 (after cffDNA), p<0.0001.
Table 1. Baseline Characteristics of Women Undergoing
Cell-free Fetal DNA Testing*
Mean maternal age (years)

32.3±6.5

Advanced maternal age

52%

Ethnicity
Caucasian

72%

Black
Asian/Indian
American Indian
Arabic
Mixed
Unknown

7%
6%
2%

AMA only

18%

Abnormal screen only

29%

Abnormal ultrasound only

37%

Abnormal screen and abnormal ultrasound
History indicated
Unspecified

13%
2%
1%

Data are in n (%).

1%
2%
11%

Non-hispanic

83%

Multiparous

64%

Married

58%

Private obstetrician

77%

Private insurance

51%

Singleton gestation

95%

High school graduate

89%

College graduate
Median gestational age (weeks)

Table 2. Primary Indications for Cell-free
Fetal DNA Testing

42%
18.64 (10.29 – 28.43)

Trimester
First

25%

Second

71%

Third

4%

* Not all characteristics available for all subjects
Data in n (%), mean +SD or median (range). GA, gestational age.

Figure 1. Volume of invasive testing for aneuploidy and cell-free fetal DNA diagnostic
tests for first year cell-free fetal DNA testing was offered
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CONCLUSIONS:
Our study provides some information on the use of new commercial tests for
aneuploidy screening using cffDNA in clinical practice in a non-research setting. The
new commercial tests available for aneuploidy screening using cffDNA were rapidly
incorporated into clinical practice and are associated with decreased use of invasive
testing for aneuploidy.
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